Long-Acting Muscarinic Antagonist
New inhaled COPD maintenance medication prescriptions rise in recent years
BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients started a new inhaled treatment in 2022, according to a presentation at the CHEST Annual Meeting.
At 4 years since COPD diagnosis, patients without treatment common
When diagnosed with COPD, 86.2% of patients did not receive treatment, and after 4 years, 63.8% still had not been treated, according to results published in BMC Pulmonary Medicine.
Inhaler combination outperforms others in reducing COPD exacerbation, cardiovascular risks
Glycopyrronium/indacaterol reduced the likelihood for severe acute exacerbations and cardiovascular events compared with tiotropium/olodaterol among patients with COPD, according to study results published in CHEST.
LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization
A long-acting muscarinic antagonist plus long-acting beta agonist (LABA) was linked to fewer COPD exacerbations and pneumonia hospitalizations vs. an inhaled corticosteroid and LABA, according to results published in JAMA Internal Medicine.
Biomarkers that predict ICS, LAMA response may differ in adults vs adolescents with asthma
Biomarkers that predict response to inhaled corticosteroid or long-acting muscarinic antagonist treatment may differ between adults and adolescents with uncontrolled mild persistent asthma, researchers reported.
COPD maintenance therapy may impact left atrial size
COPD maintenance therapy, particularly the combination of a long-acting beta agonist and long-acting muscarinic antagonist, was associated with left atrial size, according to an observational study published in Respiratory Medicine.